[Autoimmunity to glycolytic enzyme in rheumatoid arthritis].
Prognosis of rheumatoid arthritis (RA) patients has significantly improved with the recent use of biologics targeting TNFα, IL-6, and co-stimulatory molecule. In US and Europe, clear therapeutic benefit of anti-CD20 antibodies is also confirmed. As a disease specific marker, rheumatoid factor and anti-citrullinated protein antibody are crucial in RA, although the pathology of them is not defined. Here we focus on glycolytic enzyme such as glucose-6-phospate isomerase, that is confirmed as arthritogenic in two different mouse models, and discuss about pathogenic relevance to RA.
Division of Clinical Immunology, Graduate School of Comprehensive Human Science, University of Tsukuba, Japan.
Isao
I
Matsumoto
Keiichi
K
Iwanami
Yoko
Y
Tanaka
Asuka
A
Inoue
Yuki
Y
Tanaka
Naoto
N
Umeda
Takayuki
T
Sumida
D000818:Animals; D000937:Antigen-Antibody Reactions; D001172:Arthritis, Rheumatoid / Q000201:enzymology*; D015551:Autoimmunity; D004195:Disease Models, Animal; D005956:Glucose-6-Phosphate Isomerase / Q000276:immunology*; D006801:Humans; D007249:Inflammation / Q000276:immunology
D005956:Glucose-6-Phosphate Isomerase